CorMedix to buy Heron's drug portfolio for $145M cash plus stock
What's the deal? CorMedix TherapeuticsDealroom has a profile for this one. Try Dealroom → will acquire substantially all assets of Heron Therapeutics, adding four commercial-stage drugs to its hospital- and acute-care portfolio. The upfront consideration is $145 million in cash plus 14,583,333 CorMedix shares, with up to $55 million more in earn-out payments and royalties. Both boards have approved the asset purchase agreement, signed November 8, 2026.
What's being acquired? The deal brings four marketed products: ZYNRELEF for postoperative pain, APONVIE for postoperative nausea, and CINVANTI and SUSTOL for chemotherapy-induced nausea. Each is administered in hospitals, surgery centers, or infusion clinics — the institutional settings where CorMedix has built its commercial infrastructure.
Why now? Heron pursued the sale after reviewing strategic alternatives, having withdrawn its 2026 guidance amid uncertainty over potential generic competition for CINVANTI, its largest product. The transaction repays Heron's credit facility and lets it remain publicly traded, holding a significant stake in CorMedix plus rights to earn-out and royalty payments.
What's the endgame? CorMedix has been scaling beyond its lead dialysis product, reporting $101.9 million in Q2 2026 revenue — boosted by its 2025 Melinta acquisition — and commercial agreements with all five leading US dialysis providers. "This acquisition is a meaningful step forward in our strategy to build a diversified portfolio of products used in institutional settings of care," said chairman and chief executive officer Joseph Todisco. He singled out ZYNRELEF as having "significant untapped potential" as hospitals adopt non-opioid pain approaches.
How is it financed? CorMedix entered a new senior secured term loan with funds managed by Pharmakon Advisors and will draw $75 million of non-dilutive financing to support the deal. It expects the transaction to be immediately accretive to earnings and free cash flow, with $45–$60 million in near-term operating-cost synergies.
What could go wrong? The deal, expected to close in the first quarter of 2027, requires regulatory clearance and approval by Heron shareholders. Execution and the acquired products' sales prospects — especially the generic threat to CINVANTI — remain key risks to the projected accretion and synergies.
The signal: The purchase extends an acquisition-led strategy that CorMedix began with Melinta, consolidating institutional-care drugs under one commercial platform. For a company built on a single dialysis product, buying a distressed seller's marketed portfolio is a fast route to diversification — if the numbers hold.
Read more: ir.herontx.com
Image credit: NavyMedicine